Revlon Q1
This article was originally published in The Rose Sheet
Executive Summary
Firm is starting to recognize benefits from new product initiatives like relaunch of Revlon Age Defying makeup with Botafirm, CEO Jack Stahl says during May 6 analyst call. Makeup was the top-performing new product in the mass channel in Q1, Stahl points out, citing ACNielsen data, which include food, drug and mass outlets in the U.S. excluding Wal-Mart. However, Revlon brand as a whole lost market share, falling to 15.6% from 16.4% last year, while the firm's overall share was flat at 21.9%, exec notes. Success of new products was offset by performance of existing offerings, with net sales in North America falling 5.8% to $194 mil. International sales fared better, increasing 3.9% to $107 mil. Revlon net sales declined 2.4% to $300.9 mil. Net loss was $46.8 mil., compared to $58.2 mil. in Q1 2004...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.